On May 1, 2020, Varano, Flavia; Catarzi, Daniela; Vincenzi, Fabrizio; Pasquini, Silvia; Pelletier, Julie; Lopes Rangel Fietto, Juliana; Espindola Gelsleichter, Nicolly; Sarlandie, Marine; Guilbaud, Audrey; Sevigny, Jean; Varani, Katia; Colotta, Vittoria published an article.Recommanded Product: 574-98-1 The title of the article was Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A2A receptor as potential antitumor agents. And the article contained the following:
Adenosine pathway, including its generating enzyme (CD73) and its receptors represents a key target for cancer immunotherapy. Here we aimed to search for novel compounds able to co-target the CD73 and the A2A adenosine receptor (A2A AR) as dual-blockers of adenosine generation and activity. The design project was to combine in the same mol. the thiazolo[5,4-d]pyrimidine core, an essential pharmacophoric feature to block the A2A AR, with a benzenesulfonamide group which is a characteristic group of CD73 inhibitors. Most of the reported compounds resulted in inverse agonists of the human (h) A2A AR endowed with high affinity, selectivity and potency. However they were weak inhibitors of CD73 enzyme. Nevertheless, this study can be considered as a starting point to develop more active compounds The experimental process involved the reaction of 2-(2-Bromoethyl)isoindoline-1,3-dione(cas: 574-98-1).Recommanded Product: 574-98-1
The Article related to cancer immunotherapy a2aar inverse agonists cd37 inhibitor antitumor agents, adenosine a(2a) receptor inverse agonists, antitumor agents, cd73 inhibitors, cancer immunotherapy, thiazolo[5,4-d]pyrimidine and other aspects.Recommanded Product: 574-98-1
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary